Q2 2026 Talphera Inc Earnings Call Transcript
Key Points
- Talphera Inc (TLPH) has reached 75% enrollment in the NEPHRO CRRT study, with all final clinical sites activated and enrollment on track to complete later this year.
- The 2026 KDIGO clinical practice guideline now references nafamostat as an acceptable regional anticoagulant, marking the first time it has been recommended in these guidelines and providing momentum for commercialization.
- Updated market research indicates a larger market opportunity than initially estimated, with approximately 200,000 annual CRRT procedures expected in the US by 2027, a 21% increase from the prior estimate of 165,000.
- Nafamostat is already standard medical practice in Japan and South Korea, where it is the most widely used anticoagulant during CRRT, with usage in about 80% of cases in Japan.
- The company has sufficient cash, combined with future conditional financing tranches totaling approximately $16 million, to fund operations through at least a potential Niyad PMA approval expected in 2027.
- Investigators have reported that nafamostat titration is straightforward, with 80-85% of patients reaching therapeutic range at the starting dose and maintaining it without multiple adjustments, unlike heparin.
- The company has a strategic potential with CorMedix, which has a right of first negotiation for 60 days post data readout, potentially providing a commercialization pathway.
- Talphera Inc (TLPH) has a cash balance of only $17.1 million as of June 30, 2026, which may be insufficient if the conditional financing tranches do not close as expected.
- The NEPHRO CRRT study is still blinded, and the company has not yet reported top-line data, leaving uncertainty about the trial's final results.
- The KDIGO guideline currently positions nafamostat as an alternative to citrate, not a first-line therapy, which may limit initial adoption in the US where citrate is preferred in some institutions.
- The company plans to hire only a couple of employees for pre-launch activities after PMA submission, which may be insufficient for a full commercial rollout.
- The PMA filing is expected in the first half of next year, but the timeline could be delayed if the FDA requires additional meetings or data, pushing back the potential launch.
- The market opportunity is concentrated in about 70 institutions representing over 50% of procedures, making the company's success highly dependent on a small number of key accounts.
- The company has not yet provided a detailed timeline for the final KDIGO guideline publication, which could be delayed and affect commercialization momentum.
Welcome to the Talphera second-quarter 2026 financial results conference call.
This call is being webcast live via the events page of the Investors section of Talphera's website at www.talphera.com. You may listen to a replay of this webcast by going to the Investors section of Talphera's website.
I would now like to turn the call over to Raffi Asadorian, Talphera's Chief Financial Officer.
Thank you for joining us on the call today. Today, we announced our second-quarter 2026 financial results and associated business updates in a press release.
With me today are Vince Angotti, our Chief Executive Officer; and Dr. Shakil Aslam, Talphera's Chief Medical Officer.
Before we begin, I want to remind listeners that during this call, we will likely make forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties regarding the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
